Module 6: Monitoring of Treatment of Chronic Myelogenous Leukemia
This learning activity has been designated for 2.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
After completing this educational activity, the learner should be better able to:
- Select effective methods for monitoring patients with chronic myelogenous leukemia during tyrosine kinase inhibitor therapy
- Interpret quantitative polymerase chain reaction results according to the international scale
Understand the importance of detecting causes of resistance tyrosine kinase inhibitor, in particular BCR-ABL mutations
- Develop an appropriate schedule for patients’ monitoring
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Release Date: November 30, 2008
Expiration date: November 30, 2009
(*Please check this box to proceed - required)
Start the Module